Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session.
Your search for Warfarin returned 23 results
In 2017, a Work Group was assembled to conduct a systematic review of 3HP regimen studies published between January 2006 to June 2017, specifically looking at outcomes in children, individuals with HIV/AIDS, and those who self-administered treatment.
The FDA analysis evaluated the safety of Xarelto in people with nonvalvular atrial fibrillation who initiated Xarelto or warfarin from November 2011 to April 2015.
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.
Findings from a study published in the British Journal of Clinical Pharmacology showed that apixaban appeared to be an appropriate alternative to warfarin for patients with severe renal impairment.
A study published in JAMA reports that anticoagulants, antibiotics, diabetes drugs, and opioids are the most common drug classes related to emergency department visits for adverse drug events in the country.
Co-treatment with proton-pump inhibitors (PPIs) in patients initiating warfarin was associated with reduced reduced risk of warfarin-related upper gastrointestinal (GI) bleeding, a study published in Gastroenterology reported.
The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xenical (orlistat; Genentech) capsules regarding the risk of loss of virological control in patients with HIV infection taking concomitant antiretroviral agents.
A study published in JAMA found that warfarin use to prevent strokes in atrial fibrillation may not adequately manage blood clotting over time, despite patients having been stable on the drug.